Live Breaking News & Updates on Nasdaq Kpti

Stay updated with breaking news from Nasdaq kpti. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Average Recommendation of "Moderate Buy" by Brokerages

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) have been given an average recommendation of “Moderate Buy” by the five ratings firms that are presently covering the company, MarketBeat reports. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12-month […] ....

United States , Richarda Paulson , Michael Mason , Exchange Traded Concepts , Barclays Plc , Bleakley Financial Group , Karyopharm Therapeutics Company Profile , Sg Americas Securities , Selective Inhibitor Of Nuclear Export , Capital Partners , Karyopharm Therapeutics Inc , Karyopharm Therapeutics , Get Free Report , Financial Group , Traded Concepts , Get Free , Therapeutics Inc , Selective Inhibitor , Nuclear Export , Karyopharm Therapeutics Daily , Nasdaq Kpti ,

Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Crosses Below Two Hundred Day Moving Average of $1.15

Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.15 and traded as low as $0.69. Karyopharm Therapeutics shares last traded at $0.77, with a volume of 1,320,715 shares changing hands. Wall Street Analysts Forecast Growth KPTI […] ....

United States , Piper Sandler , Karyopharm Therapeutics Inc , Selective Inhibitor Of Nuclear Export , Advisor Group Holdings Inc , Royal Bank , Northern Trust Corp , Pricet Rowe Associates Inc , Karyopharm Therapeutics , Get Free Report , Trust Corp , Group Holdings , Retirement System , Pricet Rowe Associates , Therapeutics Inc , Selective Inhibitor , Nuclear Export , Karyopharm Therapeutics Daily , Nasdaq Kpti ,

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives $5.86 Consensus Target Price from Analysts

Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) has been given an average rating of “Moderate Buy” by the six brokerages that are currently covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12-month target price among […] ....

Piper Sandler , Selective Inhibitor Of Nuclear Export , Karyopharm Therapeutics Inc , Prelude Capital Management , Mercer Global Advisors Inc , Advisor Group Holdings Inc , Virtu Financial , Royal Bank , Karyopharm Therapeutics Company Profile , Karyopharm Therapeutics , Get Free Report , Group Holdings , Global Advisors , Capital Management , Get Free , Therapeutics Inc , Selective Inhibitor , Nuclear Export , Karyopharm Therapeutics Daily , Nasdaq Kpti ,

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the six ratings firms that are presently covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month price […] ....

Piper Sandler , Bleakley Financial Group , Advisor Group Holdings Inc , Prelude Capital Management , Karyopharm Therapeutics Inc , Selective Inhibitor Of Nuclear Export , Royal Bank , Simplicity Solutions , Karyopharm Therapeutics Company Profile , Karyopharm Therapeutics , Get Free Report , Marketbeat Ratings , Financial Group , Group Holdings , Capital Management , Get Free , Therapeutics Inc , Selective Inhibitor , Nuclear Export , Karyopharm Therapeutics Daily , Nasdaq Kpti ,